CUX2 prevents the malignant progression of gliomas by enhancing ADCY1 transcription

[1]  Q. Cheng,et al.  Glioma targeted therapy: insight into future of molecular approaches , 2022, Molecular cancer.

[2]  Xinchang Li,et al.  GNG7 and ADCY1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma through bioinformatic-based analyses , 2021, Scientific Reports.

[3]  Jiayi Zeng,et al.  Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas , 2021, Frontiers in Immunology.

[4]  A. Bednarek,et al.  PLEK2, RRM2, GCSH: A Novel WWOX-Dependent Biomarker Triad of Glioblastoma at the Crossroads of Cytoskeleton Reorganization and Metabolism Alterations , 2021, Cancers.

[5]  M. Buchfelder,et al.  The Acidic Brain—Glycolytic Switch in the Microenvironment of Malignant Glioma , 2021, International journal of molecular sciences.

[6]  Shuying Lin,et al.  Long non-coding RNA DPP10-AS1 exerts anti-tumor effects on colon cancer via the upregulation of ADCY1 by regulating microRNA-127-3p , 2021, Aging.

[7]  M. Mansournia,et al.  The effects of chitosan-based materials on glioma: Recent advances in its applications for diagnosis and treatment. , 2020, International journal of biological macromolecules.

[8]  Qi Ding,et al.  Forebrain overexpression of type 1 adenylyl cyclase promotes molecular stability and behavioral resilience to physical stress , 2020, Neurobiology of Stress.

[9]  Xizhe Li,et al.  Immunotherapy for glioma: current management and future application. , 2020, Cancer letters.

[10]  N. Šestan,et al.  Cux2 expression regulated by Lhx2 in the upper layer neurons of the developing cortex. , 2019, Biochemical and biophysical research communications.

[11]  T. Zhu,et al.  A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer , 2019, Journal of Cancer.

[12]  M. Nieto,et al.  The crux of Cux genes in neuronal function and plasticity , 2019, Brain Research.

[13]  K. Egan,et al.  Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma. , 2017, Seminars in cancer biology.

[14]  S. Teunissen,et al.  Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review , 2018, Journal of Neuro-Oncology.

[15]  R. Pfundt,et al.  The epilepsy phenotypic spectrum associated with a recurrent CUX2 variant , 2018, Annals of neurology.

[16]  Minghua Wu,et al.  New insights into long noncoding RNAs and their roles in glioma , 2018, Molecular Cancer.

[17]  H. Kornblum,et al.  Molecular markers in glioma , 2017, Journal of Neuro-Oncology.

[18]  Xianglong Liu,et al.  Identification of the potential biomarkers for the metastasis of rectal adenocarcinoma , 2017, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  Simran Kaur,et al.  CUX2 Protein Functions as an Accessory Factor in the Repair of Oxidative DNA Damage* , 2015, The Journal of Biological Chemistry.

[20]  R. Seifert,et al.  Membranous adenylyl cyclase 1 activation is regulated by oxidation of N- and C-terminal methionine residues in calmodulin. , 2015, Biochemical pharmacology.

[21]  L. Gunhaga,et al.  Cux2 acts as a critical regulator for neurogenesis in the olfactory epithelium of vertebrates. , 2014, Developmental biology.

[22]  Z. Li,et al.  Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. , 2010, Cancer genetics and cytogenetics.

[23]  T. Yoshimine,et al.  [Immunotherapy for glioma]. , 2008, Gan to kagaku ryoho. Cancer & chemotherapy.